Skip to main content
. 2022 Jan 18;12:750543. doi: 10.3389/fneur.2021.750543

Figure 3.

Figure 3

Representation of the increasing neurodegenerative burden in patients with ALS over time depending on their pathophysiological profile. The use of biomarkers may help to improve the current detection threshold (detection threshold and diagnostic window 1) from 1 to earlier clinical stages and differentiating between profiles (detection threshold and diagnostic window 2).